Living with paroxysmal nocturnal hemoglobinuria (PNH) means managing a condition where your immune system destroys your own red blood cells. The good news: treatment options have expanded dramatically in recent years, and most people with PNH can live full, active lives with the right combination of monitoring, medication, and awareness of their body’s signals. The challenge is that PNH touches many parts of daily life, from energy levels and blood clot risk to family planning and staying on top of lab work.
What’s Actually Happening in Your Body
PNH starts with a mutation in a single bone marrow cell. That mutation affects a gene called PIGA, which is responsible for building tiny anchors that hold protective proteins to the surface of blood cells. Two of those proteins, CD55 and CD59, normally shield red blood cells from being attacked by the complement system, a branch of your immune system that destroys foreign invaders. Without those shields, your red blood cells look like targets, and your body breaks them down constantly.
This ongoing destruction is called hemolysis, and it’s responsible for most of the symptoms you deal with: fatigue, dark urine (especially in the morning, when urine is concentrated), shortness of breath, and abdominal pain. It also releases substances into your bloodstream that increase your risk of blood clots, which is the most dangerous complication of PNH.
Treatments That Change the Equation
Six complement-blocking drugs are now FDA-approved for PNH, and the differences between them matter for your daily routine. The original treatment, eculizumab, requires an intravenous infusion every two weeks. Ravulizumab works on the same target but lasts longer, needing IV infusions only every eight weeks. Crovalimab, approved in 2024, blocks the same pathway but is a monthly injection you can give yourself under the skin at home.
A newer class of drugs works further upstream in the complement chain. Pegcetacoplan is a subcutaneous injection given twice weekly. Two oral options now exist: iptacopan, taken as a pill twice daily, and danicopan, taken three times daily. These oral treatments represent a significant shift for people who have spent years scheduling their lives around infusion appointments.
Which drug (or combination) works best depends on your specific situation, including how well your current treatment controls hemolysis and whether you experience breakthrough episodes. Switching treatments is common, and talking openly with your hematologist about how your current regimen fits your life is part of living well with PNH.
Vaccinations You Can’t Skip
Every complement inhibitor carries one important trade-off: by suppressing part of your immune defense, these drugs increase your vulnerability to meningococcal infections, which can be life-threatening. The CDC recommends both MenACWY and MenB vaccines for anyone on complement inhibitor therapy. Ideally, you should complete vaccination at least two weeks before starting treatment, though treatment can begin sooner if delaying poses a greater risk.
This isn’t a one-time requirement. MenACWY boosters are needed every five years for as long as you’re on treatment. MenB boosters are needed one year after the initial series and then every two to three years. Keeping a calendar reminder for these is a small habit that provides critical protection.
Blood Clots: The Risk You Monitor Closely
Thrombosis is the leading cause of serious complications in PNH. What makes it particularly tricky is that clots in PNH often form in unusual locations. The most common sites are the abdominal veins, including the hepatic veins (which can cause a serious condition called Budd-Chiari syndrome), the mesenteric veins serving your intestines, and the cerebral veins in your brain. Arterial clots, including in the coronary arteries, also occur at higher rates than in the general population.
Know the warning signs. Sudden, severe abdominal pain, especially with nausea or bowel changes, can signal a clot in your abdominal or mesenteric veins. An intense, unusual headache that doesn’t respond to typical remedies could indicate a cerebral vein clot. Chest pain or sudden shortness of breath warrants immediate attention. In some cases, a blood clot is actually the first sign that leads to a PNH diagnosis, so if you were diagnosed after a clotting event, you already understand how quickly things can escalate.
Complement inhibitor therapy significantly reduces clot risk, but it doesn’t eliminate it entirely. Staying physically active, staying hydrated, and being cautious during long periods of immobility (flights, bed rest after illness) all help reduce your baseline risk.
Keeping Up With Lab Work
Regular blood tests are the backbone of PNH management. Two numbers matter most at every visit: LDH (lactate dehydrogenase), which rises when red blood cells are being destroyed, and your hemoglobin level, which tells you how anemic you are. A reticulocyte count, measuring how fast your bone marrow is producing new red blood cells to replace the ones being destroyed, should also be checked at each appointment.
In untreated PNH, LDH typically rises to at least 1.5 times the upper limit of normal. On treatment, your hematologist uses LDH trends to judge how well your medication is controlling hemolysis. A sudden spike can signal breakthrough hemolysis triggered by infection, surgery, or another stressor, and may prompt a dose adjustment or additional testing.
Flow cytometry, the test that measures the size of your PNH clone (the percentage of affected blood cells), is typically repeated at least once a year. If your clone size changes significantly, your treatment plan may need to change too.
Triggers That Can Cause Flares
Even on treatment, certain situations can activate your complement system and trigger a hemolytic episode. The most common triggers are infections (even a cold or flu), surgery, physical trauma, and intense physiological stress. Pregnancy is another major trigger, covered separately below.
You can’t avoid every infection, but you can reduce your exposure through basic measures: staying current on vaccinations beyond just meningococcal (flu, COVID, pneumococcal), practicing good hand hygiene, and treating infections early rather than waiting them out. If you need surgery, even a minor procedure, your hematologist should be involved in planning. Elective surgeries may require adjusting your complement inhibitor dose or timing, and your surgical team needs to understand the clotting risks specific to PNH.
Medication adherence is one of the most important things within your control. Missing doses of a complement inhibitor can lead to rebound hemolysis, sometimes severe, as your complement system surges back to full activity against unprotected red blood cells.
Pregnancy and Family Planning
PNH adds real complexity to pregnancy, but successful pregnancies are well documented. Historically, maternal mortality was reported as high as 20%, mostly from blood clots. Modern management has improved outcomes substantially, though pregnancy with PNH is still considered high-risk.
Prophylactic anticoagulation (blood thinners to prevent clots) is recommended for all pregnant PNH patients, even those on complement inhibitors. This typically involves daily injections of a low-molecular-weight heparin, with doses adjusted based on platelet counts. For patients with active hemolysis, complement inhibitor therapy continues through pregnancy. Eculizumab has the most safety data in pregnancy, with one series of 75 pregnancies showing it to be safe and effective.
For patients with low-level hemolysis (LDH below 1.5 times normal), close monitoring with anticoagulation alone, without a complement inhibitor, may be reasonable. Either way, pregnancy with PNH requires coordination between your hematologist and a maternal-fetal medicine specialist, ideally starting before conception.
The Connection to Bone Marrow Failure
PNH doesn’t exist in isolation. It’s closely linked to aplastic anemia, a condition where the bone marrow stops producing enough blood cells. Ten to 30 percent of aplastic anemia patients develop PNH over time, and the reverse relationship exists too. If you have PNH, your bone marrow function needs ongoing monitoring because low blood counts from marrow failure compound the anemia already caused by hemolysis.
There’s also a small but real risk of progression to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), estimated at 2% to 6% of PNH patients over 7 to 10 years of follow-up. This risk is lower than in aplastic anemia patients (15% to 20% by 10 years) but is the reason your hematologist monitors your blood counts and bone marrow periodically, not just your hemolysis markers.
Managing Energy and Daily Life
Fatigue is the most persistent quality-of-life issue for people with PNH, and it often doesn’t fully resolve even with treatment. Chronic hemolysis depletes your red blood cells, and even when your hemoglobin is stable, the constant low-grade inflammation and iron loss take a toll. Some practical strategies help: pacing your activities throughout the day rather than pushing through and crashing, prioritizing sleep, and working with your doctor to address iron and folate levels, both of which are consumed rapidly when your body is constantly making new red blood cells.
The mental health dimension is real. Living with a rare, chronic condition that requires constant monitoring, regular infusions or medications, and vigilance about symptoms creates a background level of stress that compounds physical fatigue. Family education makes a measurable difference. When the people around you understand why you need to rest, why you can’t miss a treatment appointment, or why a simple cold concerns you more than it would concern them, the emotional burden lightens. Support groups for rare blood disorders, whether online or in person, connect you with people who understand the specific frustrations of PNH in a way that even supportive friends and family may not.
Financial stress is another common challenge. Complement inhibitors are among the most expensive drugs in the world. If cost is a barrier, ask your treatment team about patient assistance programs, which most manufacturers offer, and request a social worker referral to help navigate insurance coverage and copay support.